Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 16/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20792878 | 0.78 | CYP46A1 (0.49) | CYP46A1CYP3A4CYP2C9CYP2D6CYP1A2 | |
| SCHEMBL21215199 | 0.78 | CYP46A1 (0.62) | CYP46A1CYP3A4CYP2C9 | |
| SCHEMBL14849061 | 0.78 | CYP46A1 (1.00) | CYP46A1CYP3A4CYP2C9 | |
| SCHEMBL18596681 | 0.75 | CYP46A1 (0.57) | CYP46A1CYP3A4CYP2C9TSHR | |
| SCHEMBL20792745 | 0.74 | CYP46A1 (0.40) | CYP46A1CYP3A4CYP2C9TSHRCYP2D6 | |
| SCHEMBL20792873 | 0.72 | CYP46A1 (0.39) | CYP46A1CYP3A4CYP2C9TSHRCYP2D6 | |
| SCHEMBL14849010 | 0.69 | CYP46A1 (1.00) | CYP46A1 | |
| SCHEMBL14849053 | 0.67 | CYP46A1 (0.84) | CYP46A1 | |
| SCHEMBL17456008 | 0.66 | CYP46A1 (0.78) | CYP46A1CYP3A4CYP2C9TSHRLSS | |
| SCHEMBL14841158 | 0.66 | CYP46A1 (0.79) | CYP46A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157117-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157117-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | CYP46A1 3780/4885CYP3A4 4375/4885CYP2C9 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.